RxDoctor Payments Data

Rodrigo Baltodano, MD

Internal Medicine · Clermont, FLNPI 1942225164

Payments from drug & device makers

$846in general payments, 2019–2025

Across 54 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$223
  • Eisai Inc.$92
  • AstraZeneca$83
  • Amgen$74
  • Sanofi$70
  • Novo Nordisk$48
  • plus $255 from 9 others

What the payments were for

  • Speaking & faculty fees$708%
  • Food & beverage$77692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$846 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$428,385
Medicare patients
165
Services billed
3,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$82,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$50,179
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog47$43,579
Repatha SureclickEvolocumab16$16,575
EliquisApixaban18$15,810
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$11,602
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$7,132
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$6,646
Nebivolol Hcl65$2,665
Tolterodine Tartrate ErTolterodine Tartrate31$2,456
Tamsulosin Hcl112$2,276
Clonidine19$2,233
Atorvastatin Calcium246$2,211
Olmesartan Medoxomil116$1,993
Dutasteride44$1,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$48$82,55171 claims
GSKTrelegy Ellipta, Anoro Ellipta$223$61,78048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →